102 related articles for article (PubMed ID: 3553683)
1. Antithrombotic effect of TRK-100, a novel, stable PGI2 analogue.
Umetsu T; Murata T; Tanaka Y; Osada E; Nishio S
Jpn J Pharmacol; 1987 Jan; 43(1):81-90. PubMed ID: 3553683
[TBL] [Abstract][Full Text] [Related]
2. The in vitro and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analog, in several species.
Nishio S; Matsuura H; Kanai N; Fukatsu Y; Hirano T; Nishikawa N; Kameoka K; Umetsu T
Jpn J Pharmacol; 1988 May; 47(1):1-10. PubMed ID: 2842529
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban.
Kawamura M; Imura Y; Moriya N; Kita S; Fukushi H; Sugihara H; Nishikawa K; Terashita Z
J Pharmacol Exp Ther; 1996 Apr; 277(1):502-10. PubMed ID: 8613960
[TBL] [Abstract][Full Text] [Related]
4. Effect of a stable prostacyclin analogue on platelet function and experimentally-induced thrombosis in the microcirculation.
Sim AK; McCraw AP; Cleland ME; Nishio S; Umetsu T
Arzneimittelforschung; 1985; 35(12):1816-8. PubMed ID: 3913423
[TBL] [Abstract][Full Text] [Related]
5. Studies on the antiplatelet effect of the stable epoprostenol analogue beraprost sodium and its mechanism of action in rats.
Umetsu T; Murata T; Nishio S
Arzneimittelforschung; 1989 Jan; 39(1):68-73. PubMed ID: 2541730
[TBL] [Abstract][Full Text] [Related]
6. In vivo studies with the stabilized epoprostenol analogue taprostene. Effects on platelet functions and blood clotting.
Michel G; Seipp U
Arzneimittelforschung; 1990 Aug; 40(8):932-8. PubMed ID: 2242087
[TBL] [Abstract][Full Text] [Related]
7. Effects of thromboxane A2 synthase inhibitors (CV-4151 and ozagrel), aspirin, and ticlopidine on the thrombosis caused by endothelial cell injury.
Terashita Z; Imura Y; Kawamura M; Kato K; Nishikawa K
Thromb Res; 1995 Mar; 77(5):411-21. PubMed ID: 7778056
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and antiplatelet effects of the new antithrombotic agent aspalatone with low ulcerogenicity.
Han BH; Suh DY; Yang HO; Park YH; Kang YH; Kim YC
Arzneimittelforschung; 1994 Oct; 44(10):1122-6. PubMed ID: 7818584
[TBL] [Abstract][Full Text] [Related]
9. Antithrombotic effect of ticlopidine in a platelet-independent model of venous thrombosis.
Bernat A; Vallée E; Maffrand JP; Roncucci R
Thromb Res; 1985 Jan; 37(2):279-85. PubMed ID: 3975872
[TBL] [Abstract][Full Text] [Related]
10. The antiaggregating and antithrombotic activity of ticlopidine is potentiated by aspirin in the rat.
Herbert JM; Bernat A; Samama M; Maffrand JP
Thromb Haemost; 1996 Jul; 76(1):94-8. PubMed ID: 8819259
[TBL] [Abstract][Full Text] [Related]
11. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition.
Freund M; Mantz F; Nicolini P; Gachet C; Mulvihill J; Meyer L; Beretz A; Cazenave JP
Thromb Haemost; 1993 May; 69(5):515-21. PubMed ID: 8322274
[TBL] [Abstract][Full Text] [Related]
12. Antithrombotic effects of KP-10614, a novel and stable prostacyclin (PGI2) analog.
Kanayama T; Kimura Y; Iseki K; Hayashi Y; Tamao Y; Mizogami S
J Pharmacol Exp Ther; 1990 Dec; 255(3):1210-7. PubMed ID: 1702154
[TBL] [Abstract][Full Text] [Related]
13. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit.
Herbert JM; Dol F; Bernat A; Falotico R; Lalé A; Savi P
Thromb Haemost; 1998 Sep; 80(3):512-8. PubMed ID: 9759636
[TBL] [Abstract][Full Text] [Related]
14. Antiplatelet and antithrombotic efficacy of SR 121787, a nonpeptide orally active GP IIb/IIIa antagonist, in rabbits: comparison with clopidogrel and aspirin.
Hoffmann P; Bernat A; Savi P; Herbert JM
J Cardiovasc Pharmacol; 1997 Sep; 30(3):360-6. PubMed ID: 9300321
[TBL] [Abstract][Full Text] [Related]
15. Correlation between bleeding time and antithrombotic effect of platelet-suppressive agents in rat experimental model.
Suehiro A; Oura Y; Ueda M; Kakishita E
Res Commun Chem Pathol Pharmacol; 1994 Feb; 83(2):157-63. PubMed ID: 8202629
[TBL] [Abstract][Full Text] [Related]
16. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.
Sugidachi A; Asai F; Ogawa T; Inoue T; Koike H
Br J Pharmacol; 2000 Apr; 129(7):1439-46. PubMed ID: 10742300
[TBL] [Abstract][Full Text] [Related]
17. Effects of 6-[p-(4-phenylacetylpiperazin-1-yl)phenyl]-4,5-dihydro-3(2H)pyridazinone (CCI 17810) and aspirin on platelet aggregation and adhesiveness.
Griffett EM; Kinnon SM; Kumar A; Lecker D; Smith GM; Tomich EG
Br J Pharmacol; 1981 Apr; 72(4):697-705. PubMed ID: 7284687
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a stable 5-F prostacyclin analogue as an antithrombotic agent in haemodialysis.
Nicholson NS; Smith SL; Taite BB; Krueger A; Fuller GC
Drugs Exp Clin Res; 1986; 12(5):371-5. PubMed ID: 3522158
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of TA-993, a new 1,5-benzothiazepine derivative, on platelet aggregation.
Odawara A; Kikkawa K; Katoh M; Toryu H; Shimazaki T; Sasaki Y
Circ Res; 1996 Apr; 78(4):643-9. PubMed ID: 8635222
[TBL] [Abstract][Full Text] [Related]
20. Effect of 1-methyl-2-mercapto-5-(3-pyridyl)-imidazole (KC-6141) on rabbit platelet aggregation in vitro and rat platelet retention.
Umetsu T; Kato T
Thromb Haemost; 1978 Feb; 39(1):167-76. PubMed ID: 580491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
